BRPI0413906A - composições imunogênicas de hiv, kit e métodos relacionados - Google Patents

composições imunogênicas de hiv, kit e métodos relacionados

Info

Publication number
BRPI0413906A
BRPI0413906A BRPI0413906-2A BRPI0413906A BRPI0413906A BR PI0413906 A BRPI0413906 A BR PI0413906A BR PI0413906 A BRPI0413906 A BR PI0413906A BR PI0413906 A BRPI0413906 A BR PI0413906A
Authority
BR
Brazil
Prior art keywords
hiv
immunogenic compositions
mammal
immunomer
adjuvant
Prior art date
Application number
BRPI0413906-2A
Other languages
English (en)
Inventor
Ronald B Moss
Original Assignee
Immune Response Corp Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Response Corp Inc filed Critical Immune Response Corp Inc
Publication of BRPI0413906A publication Critical patent/BRPI0413906A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"COMPOSIçõES IMUNOGêNICAS DE HIV, KIT E MéTODOS RELACIONADOS". A invenção fornece composições imunogênicas que aumentam a duração e força da resposta imune em um mamífero. As composições imunogênicas contêm um antígeno de HIV, um imunómero e um adjuvante. O antígeno de HIV pode ser um vírus HIV inteiro morto desprovido da proteína do envelope externo gp120. Alternativamente, o antígeno de HIV pode ser um vírus HIV inteiro morto ou um antígeno p24. Também são fornecidos kits, cujos componentes, quando combinados, produzem as composições imunogênicas da invenção. A invenção também fornece métodos de fabricação das composições imunogênicas pela combinação de um antígeno de HIV, um imunómero e, opcionalmente, um adjuvante. A invenção ainda fornece um método de imunização de um mamífero pela intensificação de uma resposta imune no mamífero pela administração ao mamífero de uma composição imunogênica contendo um antígeno de HIV, um imunómero e, opcionalmente, um adjuvante. Também é fornecido um método de inibição em um mamífero pela administração ao mamífero de uma composição imunogênica contendo um antígeno de HIV, um imunómero e, opcionalmente, um adjuvante.
BRPI0413906-2A 2003-08-28 2004-08-27 composições imunogênicas de hiv, kit e métodos relacionados BRPI0413906A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49880403P 2003-08-28 2003-08-28
PCT/US2004/027995 WO2005021726A2 (en) 2003-08-28 2004-08-27 Immunogenic hiv compositions and related methods

Publications (1)

Publication Number Publication Date
BRPI0413906A true BRPI0413906A (pt) 2006-10-24

Family

ID=34272731

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413906-2A BRPI0413906A (pt) 2003-08-28 2004-08-27 composições imunogênicas de hiv, kit e métodos relacionados

Country Status (14)

Country Link
US (2) US20070253979A1 (pt)
EP (1) EP1670893A4 (pt)
JP (1) JP2007523884A (pt)
CN (1) CN101291691A (pt)
AP (1) AP2006003530A0 (pt)
AU (1) AU2004269379A1 (pt)
BR (1) BRPI0413906A (pt)
CA (1) CA2535527A1 (pt)
CR (1) CR8251A (pt)
IL (1) IL173740A0 (pt)
MX (1) MXPA06001996A (pt)
OA (1) OA13246A (pt)
WO (1) WO2005021726A2 (pt)
ZA (1) ZA200602246B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
EP2241325B1 (en) 2002-10-29 2012-02-08 Coley Pharmaceutical Group, Inc. Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
WO2004053104A2 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5’ cpg nucleic acids and methods of use
JP2008500963A (ja) * 2004-03-12 2008-01-17 イデラ ファーマシューティカルズ インコーポレイテッド 第二世代免疫調節性オリゴヌクレオチドを用いて増幅されたｈｉｖワクチン活性
US8431153B2 (en) 2008-09-09 2013-04-30 Celebrity Biogens, Llc Bioactive composition for the treatment of the HIV/AIDS, method for manufacturing and using the same
JP6034285B2 (ja) * 2010-05-28 2016-11-30 ゾエティス・ベルジャム・エス・アー 抗原および免疫調節ワクチンおよびコレステロール、ならびにその使用
AP2013007166A0 (en) * 2011-04-06 2013-10-31 Univ Paris Descartes Inst De Rech Pour Le Dev Ird Pharmaceutical compositions for preventing and/or treating an HIV disease in humans
CN107899009B (zh) * 2011-04-06 2021-09-17 拜欧瓦克西姆有限公司 用于预防和/或治疗人中的hiv疾病的药物组合物
US10272143B2 (en) * 2014-01-08 2019-04-30 Immunovative Therapies Ltd. Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome
TWI714529B (zh) * 2015-05-20 2021-01-01 以色列商梵提夫免疫療法公司 人類免疫缺乏病毒/後天性免疫缺乏症候群之治療

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1891A (en) * 1999-05-06 2008-09-23 The Immune Response Corp HIV immunogenic compositions and methods.
CA2435568A1 (en) * 2001-01-26 2002-08-01 The Immune Response Corporation Method for treating an hiv-infected individual by combining immunization with structured interruption of anti-retroviral treatment
KR101126030B1 (ko) * 2003-07-15 2012-03-19 이데라 파마슈티칼즈, 인코포레이티드 사이토킨 및/또는 화학치료제 또는 방사선 치료와 연계하여면역자극 올리고누클레오티드 및/또는 이뮤노머 화합물을이용하여 면역계를 공동 상승 자극시키는 방법

Also Published As

Publication number Publication date
CA2535527A1 (en) 2005-03-10
US20070253979A1 (en) 2007-11-01
AP2006003530A0 (en) 2006-02-28
IL173740A0 (en) 2006-07-05
AU2004269379A2 (en) 2005-03-10
CN101291691A (zh) 2008-10-22
WO2005021726A2 (en) 2005-03-10
US20050196411A1 (en) 2005-09-08
CR8251A (es) 2008-09-23
EP1670893A2 (en) 2006-06-21
WO2005021726A3 (en) 2008-01-17
EP1670893A4 (en) 2008-09-03
OA13246A (en) 2007-01-31
JP2007523884A (ja) 2007-08-23
MXPA06001996A (es) 2006-06-20
ZA200602246B (en) 2007-05-30
AU2004269379A1 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
BR0010323A (pt) Composições imunogênicas, kit e método de confecção da mesma para uso na imunização de um mamìfero
NL300897I2 (nl) Neisseira meningitidis serogroep B recombinant gelipideerd fHbp subfamilie A05 eiwit
EA201001189A1 (ru) Вакцинные композиции, содержащие сапониновый адъювант
BRPI0409459A (pt) novas composições imunogênicas para a prevenção e tratamento de doença meningocócica
BRPI0413906A (pt) composições imunogênicas de hiv, kit e métodos relacionados
ATE490262T1 (de) Abschwächung der immunogenizität von fusionsproteinen
WO2004043361A3 (en) Compositions and methods for the treatment of natural killer cell related diseases
IS7658A (is) Bóluefna samsetningar sem samanstanda af fitufásykrum af L2 og/eða L3 ónæmisgerð úr 1gtB mengishnettlu
MXPA02005639A (es) Induccion de respuestas celulares iinmunologicas al virus de papiloma humano y utilizacion de composiciones de peptidos y acidos nucleico.
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
BRPI0513681A (pt) composição que compreendem anticorpo her2, método, formulações farmacêuticas, polipeptìdeo, anticorpo e método de tratamento de cáncer
BR0107679A (pt) Vacina de vesìcula de membrana externa (omv) compreendendo proteìnas de membrana externa do grupo sérico b de neisseria meningitidis
ATE419008T1 (de) Adjuvante zusammensetzung und anwendungsverfahren dafür
ES2195169T3 (es) Vacunas contra calmidias y composiciones inmunogenicas que contienen un antigeno de membrana externa y metodos para su preparacion.
EP1471936A4 (en) HIV VACCINE AND METHOD OF USE
MX2007002659A (es) Composicion vacunal contra el virus de la hepatitis c.
EP1556513A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES MEDIATED BY THE HUMANE PAPILLOMA VIRUS
RU2008112497A (ru) Коньюгат для иммунизации и вакцинации и способ повышения иммуногенности
BRPI0414073A (pt) método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo
EA200301125A1 (ru) Вакцины, включающие в качестве адъюванта интерферон типа i, и связанные с этим способы
EA200300535A1 (ru) Способ получения антигенных структур, усиливающих специфическую перекрестную реактивность
BR0313121A (pt) Composição imunogênica, vacina, métodos de tratamento ou prevenção de doença neisserial, de preparação da composição imunogênica, de preparação da vacina, de preparação de uma imunoglobina para uso na prevenção ou tratamento de infecção neisserial, e de tratamento ou prevenção de infecção neisserial, usos da vacina e da preparação farmacêutica, cepa neisserial geneticamente engenheirada, imunoglobina, e, composição farmacêutica
DE60143020D1 (de) 9-alkylamino-1-nitroacridin-derivate
WO2002085409A3 (en) Methods and compositions for inducing an immune response to an antigen
EA200501367A1 (ru) Вакцинная композиция на основе ганглиозидов для подкожного введения

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.